Citadel Advisors
GRI

Citadel Advisors’s GRI Bio GRI Stock Holding History

Citadel Advisors’s Portfolio GRI Stock Details GRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$33K – 14901
2023
Q4 		$33K Buy
+2
New +$83.4K ﹤0.01% 12190
2023
Q2 		– Hold
0
– -$4.01K – 14676
2023
Q1 		– Hold
0
– – – 13995

Other funds holding GRI

ACM
Altium Capital Management New York $42M AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's GRI Position: Q1 2024 in Review

Citadel Advisors sold out of GRI Bio (GRI) in Q1 2024, closing a stake of 2 shares — an estimated $33K sold.

Citadel Advisors first reported a position in GRI in Q4 2023 and held it in 1 quarter. The position peaked at $33K in Q4 2023. 5 funds tracked by Wall St. Rank hold GRI as of Q1 2024.

  • Citadel Advisors reported no remaining GRI Bio position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 2 GRI Bio shares in Q1 2024, an estimated $33K.
  • Citadel Advisors first reported a position in GRI Bio in Q4 2023 and held it in 1 quarter.
  • Citadel Advisors's GRI Bio position peaked at $33K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held GRI Bio as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.